Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Accounts Payables: 2009-2025

Historic Accounts Payables for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $26.9 million.

  • Northwest Biotherapeutics' Accounts Payables rose 50.03% to $26.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 50.03%. This contributed to the annual value of $17.0 million for FY2024, which is 65.65% up from last year.
  • Northwest Biotherapeutics' Accounts Payables amounted to $26.9 million in Q3 2025, which was up 13.59% from $23.7 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Accounts Payables high stood at $26.9 million for Q3 2025, and its period low was $7.0 million during Q4 2021.
  • For the 3-year period, Northwest Biotherapeutics' Accounts Payables averaged around $16.6 million, with its median value being $15.1 million (2024).
  • Its Accounts Payables has fluctuated over the past 5 years, first declined by 11.15% in 2022, then surged by 65.65% in 2024.
  • Northwest Biotherapeutics' Accounts Payables (Quarterly) stood at $7.0 million in 2021, then soared by 53.20% to $10.7 million in 2022, then declined by 4.15% to $10.2 million in 2023, then surged by 65.65% to $17.0 million in 2024, then surged by 50.03% to $26.9 million in 2025.
  • Its last three reported values are $26.9 million in Q3 2025, $23.7 million for Q2 2025, and $20.7 million during Q1 2025.